XTalks

JANUARY 29, 2025

Related: Eli Lillys Kisunla (donanemab) Gets Full FDA Approval After Initial Rejection, Gears Up to Take on Leqembi Leqembi was first approved in 2023 as a monoclonal antibody targeting amyloid-beta protofibrils and plaques proteins that cause brain cell damage and cognitive decline in Alzheimers disease.

FDA Approval 66

FDA Approval Sales Antibody Protein 66

XTalks

OCTOBER 12, 2021

14-3-3 zeta) protein, which the UToledo researchers had been studying for its role in immune-related pathologies, such as aortic aneurysms and in signaling pathways involving the pro-inflammatory cytokine interleukin-17. However, they found the opposite to be true, where the protein was actually protective against development of the disease.

Vaccination 105

Vaccination Vaccine Research Immune Response 105

pharmaphorum

JULY 18, 2022

. “It is programmed and coded for the production of the full-length spike protein of the coronavirus. It then elicits an immune response against that spike protein. You have a response with immunoglobulins type G (antibodies) and robust cellular response with both CD4 and CD8 T-cells being activated,” Morgon states.

Vaccination 138

Vaccination Vaccine Development Immune Response 138

Pharmaceutical Technology

APRIL 26, 2023

This investment will be used to further the development of the Singapore-based pharmaceutical company’s solid tumour-focused monoclonal antibodies. The Amgen Golden Ticket awards support to early life science businesses by offering them resources for business development.

Development 256

Development Drugs Marketing Protein 256

The Pharma Data

SEPTEMBER 4, 2020

The technique has been used to generate a high-affinity antibody against Arginase 2, an enzyme implicated in major human diseases. Therefore, the enzyme is a target for inhibitory therapeutic antibodies that could help restore immune function against cancer cells, the researchers note.

Antibody 52

Antibody Research Life Science Production 52

XTalks

MAY 9, 2024

Genmab, a trailblazer in the field of antibody therapeutics, celebrates this milestone by reflecting on its impressive journey from a small-scale startup to a global leader in cancer treatment and beyond. Since then, innovative science has been at Genmab’s core, as we harness the power of human antibodies to improve the lives of patients.

Antibody 52

Antibody Clinical Trials Clinical Trials Medicine 52

XTalks

JULY 25, 2022

Epidermal growth factor receptor 2 (HER2)-positive breast cancer is one such type in which there is an overexpression of the HER2 protein. Later lines of treatment can include monoclonal antibodies, tyrosine kinase inhibitors and antibody-drug conjugates (ADCs). Vic-]Trastuzumab Duocarmazine Mechanism of Action.

Antibody 59

Antibody Drugs Clinical Trials Clinical Trials 59

XTalks

FEBRUARY 26, 2024

Xolair is a monoclonal antibody that binds to IgE, a type of antibody in the body that triggers allergic reactions, to block it from binding to its receptors. Xolair is the first medication approved by the FDA to reduce allergic reactions to more than one type of food after accidental exposure.

Allergies 100

Allergies FDA Approval Drugs Protein 100

XTalks

APRIL 9, 2025

Primary IgAN is a rare autoimmune disease in which deposits of IgA provoke glomerular inflammation and excessive protein leakage into the urine. Beyond Vanrafia, Novartis is advancing zigakibart, a subcutaneously administered antiAPRIL monoclonal antibody in PhaseIII development for IgAN.

FDA Approval 59

FDA Approval Clinical Trials Clinical Trials Trials 59

XTalks

JANUARY 6, 2025

However, some patients develop inhibitors antibodies that neutralize the efficacy of replacement therapies. These inhibitors make managing bleeding episodes more challenging, increasing the risk of severe complications such as joint damage, chronic pain and life-threatening hemorrhages. Hympavzi is administered once weekly.

FDA Approval 105

FDA Approval Antibody Drugs Clinical Trials 105

pharmaphorum

JULY 20, 2021

The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi’s vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by GSK that aims to boost its efficacy. 1.351) variant first identified in South Africa.

Vaccination 98

Vaccination Vaccine Protein Immune Response 98

Pharmaceutical Technology

MARCH 1, 2023

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck KG, is a science and technology company. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. It is a new chemical entity. Merck overview Merck, a subsidiary of E.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

Pharmaceutical Technology

MARCH 1, 2023

The drug candidate targets DNA-dependent protein kinase (DNA-PK). Merck KG, is a science and technology company. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. It is a new chemical entity. Merck overview Merck, a subsidiary of E.

Gene Editing 100

Gene Editing DNA Cosmetics Life Science 100

pharmaphorum

MARCH 28, 2022

Israel-based AION Labs and German independent research institute BioMed X announced its third global call for applications to form a new start-up company focused on using AI to design and optimise antibodies for targeted therapies. . The partners want to focus on riskier, more complex structures of proteins to try to decipher them.

Pharma Companies 98

Pharma Companies Antibody Protein Development 98

XTalks

OCTOBER 22, 2024

Vyloy is a first-in-class monoclonal antibody that targets the CLDN18.2 transmembrane tight junction protein, which is commonly found in some gastric and GEJ cancers. gene, and an estimated 60 percent of all gastric cancers harbor the protein. targeting antibody-drug conjugate. On the other hand, Merck & Co.

FDA Approval 105

FDA Approval Drugs Licensing Licensing 105

XTalks

APRIL 7, 2021

As the COVID-19 pandemic shifts with new case surges largely owing to new variants of SARS-CoV-2, the US Food and Drug Administration (FDA) continues to offer up emergency use authorizations (EUA) for tests for the detection of COVID-19 infection, with the latest being antibody and antigen tests from Symbiotic and Quidel, respectively.

Antibody 102

Antibody Immune Response Radiology Marketing 102

XTalks

OCTOBER 23, 2024

Sibeprenlimab, which has a Breakthrough Therapy designation, is a monoclonal antibody that blocks APRIL ( A PR oliferation- I nducing L igand), a critical step in the immune cascade contributing to IgAN. IgAN, also known as Berger’s disease, occurs when IgA antibodies build up in the kidneys, leading to inflammation.

Trials 101

Trials Clinical Trials Clinical Trials Antibody 101

XTalks

DECEMBER 12, 2023

Plasma medicine is a critical and specialized field within healthcare, centering on the use of human plasma for the development and administration of life-saving treatments. Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

XTalks

JULY 10, 2023

Rystiggo received FDA approval under the Priority Review designation, specifically for the treatment of gMG in adult patients who have tested positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The active ingredient in Rystiggo is rozanolixizumab, a humanized IgG4 monoclonal antibody.

FDA Approval 98

FDA Approval Antibody Protein Engineer 98

XTalks

JANUARY 31, 2022

Neutralizing Antibody Data for Omicron Targeting. Moderna also announced publication of neutralizing antibody data against omicron following a booster dose of its original vaccine, mRNA-1273, in the New England Journal of Medicine (NEJM) this month. The study showed that antibody neutralization against omicron decreased by 6.3-fold

Vaccination 98

Vaccination Vaccine Trials Antibody 98

XTalks

APRIL 22, 2022

Generally, antibody-based therapeutics are one of the main types of drugs that are assessed using receptor occupancy assays as they bind to specific cell surface receptors through which they impact downstream intracellular signalling pathways. The antibodies are conjugated to fluorochromes for them to be detected.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Antibody 98

XTalks

JUNE 16, 2021

The company’s candidate recombinant nanoparticle protein-based COVID-19 vaccine, NVX-CoV2373, is being evaluated in the PREVENT-19 (the PRE-fusion protein subunit Vaccine Efficacy Novavax Trial COVID-19) Phase III trial, which has close to 30,000 participants across 119 states in the US and Mexico.

Vaccination 98

Vaccination Vaccine Protein Trials 98

Delveinsight

JULY 29, 2021

billion in biobucks on the table to buy Teneobio and its suite of bispecific and multispecific antibody technologies focused on cancer and other disease targets. An antisense treatment, BIIB080 potentially aims at microtubule-linked protein tau (MAPT) messenger RNA (mRNA) and impedes tau protein production.

Drugs 98

Drugs Protein Life Science Development 98

XTalks

MAY 26, 2022

Monoclonal Antibody Technology Behind Dupixent’s Efficacy. Dupixent was developed with VelocImmune® , a human monoclonal antibody technology from Regeneron that inhibits interleukin-4 (IL-4) and IL-13 signaling pathways. Live and On-Demand: Monday, June 20, 2022, at 1pm EDT (10am PDT).

FDA Approval 105

FDA Approval Antibody Clinical Trials Clinical Trials 105

XTalks

JANUARY 26, 2023

Tyrosine Kinase Inhibitors for Cancer Treatment Tyrosine kinases, or TKs, are a group of signaling molecules that affect multiple downstream proteins. As with many cancers, CLL and SLL are more difficult to treat in the relapse/refractory setting.

FDA Approval 97

FDA Approval Life Science Clinical Trials Clinical Trials 97

Pharma in Brief

DECEMBER 17, 2023

On December 4, 2023, the Federal Court held that a patent claiming a formulation of adalimumab, a monoclonal antibody used to treat autoimmune diseases, is valid and is being infringed by a biosimilar product. The Court found that this publication disclosed adalimumab and self-buffering protein formulations.

Antibody 52

Antibody Production Regulation Marketing 52

XTalks

JULY 2, 2021

Conspiracy theories citing similarities between a placental protein called syncytin-1 and the spike protein of the coronavirus started doing the rounds last year, claiming that vaccines based on this spike protein could cause the immune system to attack the placenta and lead to pregnancy issues.

Vaccination 105

Vaccination Vaccine Protein Immune Response 105

pharmaphorum

FEBRUARY 22, 2022

Microlyse is a thrombolytic fusion protein that targets von Willebrand factor (vWF), a glycoprotein in the blood that is a carrier protein for Factor VIII and is part of the process that causes platelets to stick together in clot formation. The post TargED Bio raises €39m for new clot-busting drug appeared first on.

Drugs 59

Drugs Protein Clinical Development Antibody 59

The Pharma Data

SEPTEMBER 15, 2020

The companies will receive priority admission or renewal for one year of lab bench space with access to core facilities at the MBC BioLabs life sciences incubator, including access to Amgen ‘s scientific experts and business leaders to help advance their scientific programs.

Life Science 52

Life Science Protein Antibody Scientist 52

XTalks

JULY 25, 2023

Cyfendus functions by stimulating the production of antibodies targeted against the protective antigen protein. These antibodies play a crucial role in providing protection by effectively neutralizing the cytotoxic lethal toxin and edema toxin of B. The recommended administration involves two doses, each of 0.5 Overall, 66.3

FDA Approval 98

FDA Approval Vaccination Vaccine Antibody 98

XTalks

DECEMBER 14, 2021

The quadrivalent influenza vaccine candidate, mRNA-1010, is targeted against hemagglutinin (HA) proteins from four seasonal influenza viruses, which include two influenza A subtypes, H1N1 and H3N2, and two influenza B subtypes, Yamagata and Victoria. Antibody levels against the A strains were higher than the B subtypes.

Vaccination 98

Vaccination Vaccine Immune Response Antibody 98

XTalks

AUGUST 30, 2022

The hemophilia A gene therapy Roctavian delivers a functional gene to enable the body to make an essential blood clotting protein on its own. A lack of sufficient functioning factor VIII and factor IX blood clotting proteins would result in the development of hemophilia A and hemophilia B, respectively.

Gene Therapy 98

Gene Therapy Gene Clinical Trials Clinical Trials 98

XTalks

MAY 2, 2023

Tezspire is the first treatment for asthma that targets thymic stromal lymphopoietin, a protein involved in airway inflammation. It is a monoclonal antibody that works by blocking interleukin-4 (IL-4) and interleukin-13 (IL-13), two proteins that are involved in the inflammation process in asthma.

Protein 109

Protein FDA Approval Clinical Trials Clinical Trials 109

XTalks

JUNE 15, 2022

The Novavax candidate NVX-CoV2373 is a protein-based vaccine developed using recombinant nanoparticle technology. protein that triggers the immune system to generate antibodies against the virus. If approved, NVX-CoV2373 would become the first available protein-based vaccine against COVID-19 in the US.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

XTalks

AUGUST 2, 2022

Benlysta (belimumab) is a biologic therapy, a human monoclonal antibody. Autoreactive B cells release antibodies like other B cells do, except they release autoantibodies. B cells require a specific protein for growth called BLyS (B-lymphocyte stimulator), which is implicated in the pathogenesis of SLE.

FDA Approval 94

FDA Approval Antibody Bacteria Protein 94

XTalks

JUNE 30, 2023

Hemophilia A is a rare genetic bleeding disorder that is caused by a mutation in the gene that encodes the key blood clotting protein factor VIII (FVIII). Severe hemophilia A is usually treated with FVIII replacement therapy or an antibody-based drug to improve the ability of blood to clot and reduce the likelihood of bleeding.

Gene Therapy 98

Gene Therapy Gene FDA Approval Antibody 98

XTalks

JULY 27, 2021

The anti-amyloid beta monoclonal antibody was initially handed a broad label approval by the US Food and Drug Administration (FDA) in June. Anti-Amyloid Beta Monoclonal Antibodies and Aduhelm Controversy. This is in light of conflicting results from trials over the past couple of years. Adulhelm Considerations.

Antibody 98

Antibody Drugs Trials Clinical Trials 98